Danaher Co. (NYSE:DHR) Shares Sold by Fulton Bank N.A.

Fulton Bank N.A. lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 1.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,963 shares of the conglomerate’s stock after selling 182 shares during the quarter. Fulton Bank N.A.’s holdings in Danaher were worth $2,738,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Norges Bank acquired a new position in Danaher during the 4th quarter worth $1,752,382,000. Wellington Management Group LLP grew its position in shares of Danaher by 18.6% in the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after acquiring an additional 3,905,449 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in Danaher by 214.4% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock worth $711,051,000 after purchasing an additional 2,096,038 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after purchasing an additional 1,619,586 shares during the period. Finally, Capital International Investors increased its stake in Danaher by 9.1% during the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after purchasing an additional 1,334,781 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. TD Cowen lifted their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Robert W. Baird increased their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Citigroup boosted their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Jefferies Financial Group began coverage on Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price on the stock. Finally, Barclays boosted their price target on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus target price of $269.29.

Danaher Price Performance

NYSE DHR traded down $8.81 on Thursday, reaching $248.70. 6,112,145 shares of the stock traded hands, compared to its average volume of 2,808,469. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $269.11. The company has a market cap of $184.21 billion, a price-to-earnings ratio of 42.15, a P/E/G ratio of 3.94 and a beta of 0.85. The firm’s fifty day simple moving average is $254.16 and its 200 day simple moving average is $245.03. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same period in the previous year, the company earned $2.36 earnings per share. Danaher’s revenue was down 2.6% compared to the same quarter last year. As a group, research analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.27 dividend. The ex-dividend date is Friday, June 28th. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. Danaher’s dividend payout ratio is currently 18.31%.

Insider Transactions at Danaher

In other news, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the transaction, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The disclosure for this sale can be found here. Insiders sold a total of 148,783 shares of company stock valued at $37,536,717 in the last three months. 11.10% of the stock is currently owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.